Chief Executive Officer · BioXcel Therapeutics, Inc. (BTAI)

Vimal Mehta

A named executive officer of BioXcel Therapeutics in every fiscal year CompBrief holds from FY2023 to FY2024. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2024

$1,119,245

Salary $1,001,570Stock awards $0

FY2023: $4,731,147

1st of 3 named executive officers at BioXcel Therapeutics by FY2024 total.

3 named officers on file for BioXcel Therapeutics, FY2024

Vimal Mehta’s pay file — $29

  • 2 fiscal years of pay, line by line
  • 2 equity grants, each cited to its filing

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how BioXcel Therapeutics’s whole pay program stands against its peers

  • BioXcel Therapeutics’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on BTAI→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed November 12, 2025 (DEF 14A). Insider transactions since that proxy, current to 2026-11-21.

Free

Get Vimal Mehta’s full pay file as a PDF — free

More than this page: up to 10 years of Vimal’s pay history, a side-by-side peer comparison, and a one-page board summary — the whole file, yours now and by email.

Vimal Mehta compensation by year

BioXcel Therapeutics Summary Compensation Table · all 2 fiscal years held
In US dollars, as BioXcel Therapeutics reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2023FY2024
Salary$1,001,569$1,001,570
Bonus$0$0
Stock awards$1,097,600$0
Option awards$2,615,928$101,250
Non-equity incentive$0$0
Pension and deferred compensation$0$0
All other$16,050$16,425
Total$4,731,147$1,119,245

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: BioXcel Therapeutics, Inc. DEF 14A filed November 12, 2025, accession 0001104659-25-110491, and prior-year filings. Open the filing on EDGAR.

How this page was built: the BioXcel Therapeutics, Inc. filed document, accession 0001104659-25-110491. Every figure is read from that document and cited to the page and table it appears in. Filed November 12, 2025.

$4.7M
$1.1M
FY23
FY24
SalaryStock awardsOption awardsAll other

Equity holdings

unvested awards at FY2024 year-end
TypeUnvested unitsValue at year-endExercise price
PSU15,625$93,475—
RSU1,969$11,779—
RSU816$4,882—
Option978—$658.72
Option3,268—$244.96
Option5,913—$313.60
Option6,250—$19.20

Per the Outstanding Equity Awards at Fiscal Year-End table in BioXcel Therapeutics, Inc.'s FY2024 proxy; value at the fiscal year-end close, as the company printed it.

Insider transactions since the last proxy

16 Form 4 lines since the FY2024 proxy (filed November 12, 2025)
current to 2026-11-21 · updated nightly
DateTransactionPlanSharesPriceHeld after
2026-06-15Exercise or conversion derivative—219$0.001,313
2026-06-15Exercise or conversion—219—69,817
2026-05-20Sale10b5-119,419$1.0969,598
2026-05-04Exercise or conversion derivative10b5-149,758$0.00149,274
2026-05-04Exercise or conversion10b5-149,758—89,017
2026-05-01Exercise or conversion—18,000—39,259
2026-05-01Exercise or conversion derivative—18,000$0.000
2026-03-15Exercise or conversion derivative—219$0.001,532

The 8 most recent of 16 lines, each as reported on the Form 4. "10b5-1" marks a trade the filing reports under a pre-arranged trading plan. View every Form 4 filing on EDGAR →

BioXcel Therapeutics’s named executive officers, FY2024

as the company reported each
Named executive officerRoleFY2024 total
Vimal Mehta · this pageChief Executive Officer$1,119,245
Javier RodriguezSenior VP and Chief Legal Officer$1,012,552
Richard SteinhartSVP and Chief Financial Officer$998,216

The full BioXcel Therapeutics compensation record

free company brief

This page is one person within BioXcel Therapeutics's record. The company brief lists every named executive, each linking to their own page.

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are BioXcel Therapeutics's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Vimal Mehta's compensation dossier · One-time report. No refunds.